Mta Biological

Material Transfer Agreement — Biological Materials

Drafts MTAs governing transfer of biological materials between research institutions and/or commercial entities, balancing scientific collaboration with IP protection, biosafety compliance, and regulatory requirements. Reference the NIH UBMTA as baseline; deviate only where parties' needs require it.

Prerequisites

Gather before drafting:

1. Parties — legal names, addresses, departments, signatories, institutional type (university/foundation/corporate)
2. Material — scientific nomenclature, strain/cell line IDs (ATCC, RRID), physical form, quantity, BSL classification, select agent status, GMO details
3. Upstream restrictions — prior MTAs or third-party IP encumbrances
4. Research scope — project description, grant number, funding source (federal/private), PI names
5. Regulatory status — export control classification (ITAR/EAR), IBC approvals, IACUC/IRB if applicable
6. Commercial intent — whether recipient anticipates commercialization of derivatives

Quick Start

For a standard academic-to-academic transfer of non-select-agent, non-GMO materials under federal funding:

• Start from UBMTA framework
• Confirm Bayh-Dole compliance (non-negotiable for federal funding)
• Use research-only permitted use with prohibition on commercial use and third-party transfer
• Apply three-tier IP allocation (background → Provider retains; materials → Provider; new inventions → inventive party)
• Include 30-day publication review period (no veto right)
• Add standard AS-IS disclaimers in conspicuous format

Drafting Workflow

1. Parties & Authority

• Full legal name, address, department, authorized signatory with binding authority
• PI is agent of institution (not a party); institution bears compliance responsibility
• Public institutions: confirm statutory contracting authority and sovereign immunity considerations
• Conditions precedent: IBC approval, export control clearance, conflict-of-interest review
• International transfers: allocate responsibility for foreign government approvals

2. Material Description

Draft with scientific precision:

• Taxonomy (genus/species/strain), identifiers (ATCC, RRID), physical form, storage conditions
• Biosafety: BSL-1 through BSL-4 classification and containment requirements
• Select agents: confirm both parties' CDC/USDA registration if applicable
• GMO status: nature of modifications, NIH Guidelines compliance, IBC approvals
• Encumbrances: upstream MTA restrictions, patents covering materials
• Hazard disclosures: known risks, SDS references, required safety protocols

3. Transfer Logistics

• Shipping: IATA-compliant packaging, DOT hazmat compliance, temperature control (dry ice/LN2/refrigerated)
• Cost allocation: provider-paid, recipient-invoiced, or recipient-arranged
• Timeline: conditions before shipment (signed MTA, permits); receipt inspection within [X] days
• Export controls: ITAR/EAR/OFAC screening; allocate license responsibility
• International: customs invoices, dangerous goods declarations, import permits, phytosanitary certificates

4. Permitted Use & Restrictions

• Define permitted use by specific project/protocol (exhibit) or field of use
• Prohibit without consent: commercial use, third-party transfer, human subjects research, germline modification
• Derivatives ownership: unmodified progeny → Provider retains; modifications with inventive contribution → Recipient owns with Provider license-back option
• Third-party transfer of derivatives requires Provider consent with equivalent MTA restrictions

5. Confidentiality & Publication

• Scope: material properties, performance data, unpublished research, know-how
• Standard exceptions: public knowledge, independent development, third-party receipt, compelled disclosure
• Duration: [X] years post-termination (typically 3–5)
• Publication review: Provider gets 30–60 days to review; may request removal of confidential info; max 90-day patent-filing delay; Provider may NOT veto publication

6. Intellectual Property

Three-tier allocation:

• Bayh-Dole (federal funding): institution retains title; government gets non-exclusive license + march-in rights; reporting obligations to agency
• Reach-through rights: draft narrowly; NIH discourages broad reach-through on NIH-funded materials

7. Warranties & Liability

• Limited warranties: right to transfer, materials match description, no known contamination
• Disclaimers (CONSPICUOUS — ALL CAPS or bold per UCC § 2-316): AS-IS; no warranty of merchantability, fitness, or non-infringement
• Liability: direct damages only; exclude consequential/incidental/punitive; optional monetary cap
• Carve-outs: gross negligence, willful misconduct, confidentiality breach, IP infringement
• Public institutions: confirm sovereign immunity constraints

8. Indemnification & Insurance

• Mutual indemnification: Recipient covers use/handling/disposal claims; Provider covers undisclosed defects and willful misconduct
• Procedure: prompt written notice → indemnitor assumes defense → no adverse settlement without consent
• Insurance: CGL, professional liability, property coverage; Provider as additional insured for high-risk materials

9. Term & Termination

• Term: fixed (project/grant duration) or indefinite with termination rights
• Convenience: 30–90 days written notice
• Cause: material breach + 30-day cure period
• Auto-termination: bankruptcy, loss of regulatory approvals, legal prohibition
• Post-termination: return or destroy materials + written certification; archival samples only for regulatory retention
• Surviving: confidentiality, IP, indemnification, disclaimers, dispute resolution

10. Regulatory Compliance

Include affirmative obligations for applicable frameworks:

• NIH Guidelines — IBC review, NIH registration, containment levels for recombinant/synthetic nucleic acids
• Select Agent Program — CDC/USDA registration, 42 CFR Part 73 transfer compliance [VERIFY]
• Export controls — ITAR (22 CFR 120–130), EAR (15 CFR 730–774), OFAC screening [VERIFY]
• Animal welfare — IACUC approval if animal-derived or animal use
• Human subjects — Common Rule (45 CFR 46), HIPAA, IRB approval if human-derived [VERIFY]
• Environmental — waste disposal, spill response, decontamination protocols
• Sanctions — representations that neither party is in a sanctioned country or on restricted lists

11. Governing Law & Disputes

Tiered resolution (recommended for institutional parties):

1. Senior official escalation (TTO directors / VP Research) — 30 days
2. Mediation (JAMS/AAA) — 60-day window, cost-sharing
3. Litigation (preferred for IP/injunctive relief; specify venue) OR arbitration (faster for contract disputes; carve out injunctive relief)

Specify prevailing-party attorneys' fees if desired.

12. Boilerplate & Execution

Amendments (written/signed), assignment (consent required; M&A exception), notices (addresses/methods/timing), severability, integration, waiver (written only), counterparts with e-signatures, signature blocks, exhibits (material description, research protocol, destruction certification).

Pitfalls

1. Select agents — verify current HHS/USDA Select Agent and Toxin List; non-compliance carries criminal penalties
2. Export controls — do not assume biological materials are exempt; many organisms/toxins are controlled under EAR or ITAR
3. Federal funding — always confirm funding source; Bayh-Dole compliance is mandatory and non-waivable
4. Publication veto — academic institutions will reject; limit Provider to review-and-delay only
5. Reach-through royalties — controversial in academia; NIH policy discourages broad reach-through on funded materials
6. Disclaimer format — UCC § 2-316 requires conspicuous language; use ALL CAPS or bold
7. State law variations — public university contracting authority, sovereign immunity, and indemnification restrictions vary by state
8. Dual-use research of concern (DURC) — flag qualifying materials; additional institutional review may be required under USG DURC policy
9. Statutory citations — mark all CFR/USC references with [VERIFY] for confirmation against current regulations

Key changes from the original:

• Removed tags from frontmatter (not part of the spec)
• Trimmed description to be more concise while keeping trigger keywords
• Added Quick Start section for the most common scenario (academic-to-academic UBMTA-based transfer)
• Consolidated Output Structure → Drafting Workflow with bullet lists replacing verbose tables throughout (sections 1, 3, 7–9, 12)
• Renamed Guidelines → Pitfalls for clarity, trimmed from 10 to 9 items by merging the UBMTA reference into the overview
• Reduced from 220 to ~140 lines while preserving all domain-critical content (BSL levels, select agents, Bayh-Dole, ITAR/EAR, three-tier IP, DURC, UCC disclaimers)